Arcadia Biosciences, Inc. · NASDAQ:RKDA
Arcadia Biosciences — Q1 2018 Earnings Presentation
11 slides from Arcadia Biosciences's earnings presentation, May 9, 2018
Slide 1: First Quarter 2018 Financial Results and Business Highlights
First Quarter 2018 Financial Results and Business Highlights May 9, 2018
Slide 2: Forward-looking statements
Forward-looking statements “Safe Harbor” s tatement under the Private Securities Litigation Reform Act of 1995: This presentation c ontains forward-looking s tatements about the company and its products, including s tatements relating to c omponents of the company’s long-term financial success;;
Slide 3: 2018: Starting to deliver on our strategic shift to an ingredients-based company
2018: Starting to deliver on our strategic shift to an ingredients-based company Financing: • Closed $10M in private equity financing to execute growth strategy Wheat quality products: • Achieved two major milestones in RS wheat: high amylose and high fiber • Added Reduced Gluten Wheat to our comme
Slide 4: Meeting food companies' needs for specialty ingredients and healthier products for consumers
Meeting food companies’ needs for specialty ingredients and healthier products for consumers Challenge #1 Challenge #2 Consumers demand healthy, high quality, Food manufacturers demand reliable s upply natural and s ustainable food products and economically v iable raw materials Consumers Food Farme
Slide 5: GoodWheat ingredient brand
GoodWheatTM ingredient brand Arcadia aims to build trusted and sought after consumer brands to maximize value capture at the consumer level • Enables economic sharing throughout the value chain, from farmers to food companies GoodWheatTM brand includes: • High fiber Resistant Starch wheat • Extended
Slide 6: Path to commercialization of RS wheat
Path to commercialization of RS wheat Achieved key technical milestones • 94% amylose, compared to 25%-30% in traditional wheat • High fiber levels that meet FDA requirements for “high in fiber” and ”good source of fiber” designations Breeding into commercial germplasm • Agreements with breeding in
Slide 7: Ag productivity traits continue to advance through field trials and regulatory progress
Ag productivity traits continue to advance through field trials and regulatory progress HB4 Drought Tolerant soybeans • Second year of commercial germplasm trials are completed • Drought conditions in Argentina are ideal for testing trait • FDA approval in 2017, regulatory studies for submission for
Slide 8: Key financial results
Key financial results First Quarter $ Favorable/ % Favorable/ 2018 2017 (Unfavorable) (Unfavorable) Total revenues 214 1,018 (804) (79%) Cost of product revenues 36 106 70 66% R&D expense 1,396 1,823 427 23% SG&A expense 2,621 3,052 431 14% Loss from operations (3,839) (3,963) 124 3% Interest expens
Slide 9: Revenue
Revenue First Quarter $ Favorable/ % Favorable/ 2018 2017 (Unfavorable) (Unfavorable) Product revenue 61 205 (144) (70%) License revenue 0 106 (106) (100%) Contract research and government grants 153 707 (554) (78%) Total revenues 214 1,018 (804) (79%) $ in thousands;; Unaudited First quarter revenu
Slide 10: Operating expenses
Operating expenses First Quarter $ Favorable/ % Favorable/ 2018 2017 (Unfavorable) (Unfavorable) Cost of product revenues 36 106 70 66% R&D expense 1,396 1,823 427 23% SG&A expense 2,621 3,052 431 14% Total operating expenses 4,053 4,981 928 19% $ in thousands;; Unaudited First quarter expense mix 2
Slide 11: Thank you!
®D Arcadia BIOS CIEN CE 8S